Metal-metal Articulations Versus Standard 28 mm Cementless Total Hip Arthroplasty

NCT01113762 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2017-12-19

No results posted yet for this study

Summary

Younger hip patients often need revision of their hip replacement due to wear and loosening. Newer concepts (resurfacing and large head total hip replacement) with articulation surfaces in metal may reduce the wear, increase the longevity of the implant and give an improved function. The possible downside is that these concepts releases metal debris to the body. The investigators wish to see if the newer interventions are a clinical improvement compared to standard. The investigators also wish to investigate the extent of metal released to the body and any effect on the immune system. Finally the investigators wish to investigate the stability of these new implants and their ability to preserve the bone around the implant.

The investigators hypothesis is:

That the metal on metal articulations will not have better clinical outcomes than standard The resurfacing implant is expected to preserve the bone of the upper femoral bone. The implants are expected to be stabile within the first year.

Conditions

  • Osteoarthritis, Hip

Interventions

DEVICE

articular surface replacement ASR, DePuy

posterolateral incision

DEVICE

ReCap/Magnum modular head, Biomet

posterolateral incision

DEVICE

Bimetric stem, mallory/head cup, 28 mm ceramic head, Biomet

posterolateral incision

DEVICE

28 mm CrCo head, Trilogy CH cup, VerSys Fiber stem,Zimmer)

posterolateral incision

Sponsors & Collaborators

  • Ministry of the Interior and Health, Denmark

    collaborator OTHER_GOV
  • Region Zealand

    collaborator OTHER
  • Zimmer Biomet

    collaborator INDUSTRY
  • DePuy Orthopaedics

    collaborator INDUSTRY
  • University of Southern Denmark

    lead OTHER

Principal Investigators

  • Soeren Overgaard, MD, professor, phd · University of Southern Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2009-11-30
Completion
2019-11-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01113762 on ClinicalTrials.gov